Advancing Cancer Drug Discovery with a Data-Driven Approach

The article highlights our approach to combining multi-omics and advanced molecular profiling to improve cancer drug discovery. Central to our strategy is a biobank of high-quality, rapidly frozen tumor samples, which allows for accurate analysis of tumor heterogeneity and variability between individual patients.

By leveraging our data-driven approach, we can uncover unique insights into tumor biology. Achieving significant results requires not only the right quantity and quality of tissue samples, but also advanced analytical, computational, and biochemical expertise to identify new therapeutic targets and potential drug candidates.

Read the full article based on an exclusive interview with our Head of R&D here.